Prevention Of Infection In Immunosuppressive Patients With Autoimmune Nephrosis By Using An Immunostimulating Bacterial Lysate: OM-85BV

Objective The present trial was to investigate the efficacy and safety of OM-85BV onpreventing infection in immunosuppressive patients with autoimmune nephrosis.Methods40patients with autoimmune nephrosis were divided into two groups. The controlgroup (20cases) routinely received corticosteroid and (or) immunosuppressive therapy,while the treatment group (20cases) received a capsule containing7mg OM-85BV dailyfor the first10days of each month for3consecutive months on the basis of conventionalcorticosteroid and (or) immunosuppressive therapy. The condition of infection, the outcomeof original disease, blood lymphocyte and serum immunoglobulin was assessed.Result4patients in the treatment group and5patients in the control group were lost duringthe follow-up period.25%patients in the control group and40%in the treatment groupsuffered infection. There was no difference in the incidence of infection between the twogroups (p>0.05). OM-85BV–treated patients suffered a shorter infection period and ofwhich fewer patients need to receive antibiotics therapy (p<0.05). After the treatment withOM-85BV, the proportion of blood T lymphocyte, CD4+T lymphocyte, CD4+T/CD8+Treduced less and the serum IgG rose more obviously (p<0.05), but the change of bloodlymphocyte, B lymphocyte, CD8+T lymphocyte, IgA and IgM have no differences betweenthe two groups(p>0.05).Conclusion OM-85BV could improve the immune level of autoimmune nephrosis andmight be a good choice for preventing the respiratory infection in autoimmune nephrosis, especially who accepts the corticosteroid and immunosuppressant therapy.